142 results match your criteria: "Rhinitis Medicamentosa"
J Clin Sleep Med
November 2024
Indiana University School of Medicine, Department of Internal Medicine, Division of General Internal Medicine.
Adherence to positive airway pressure (PAP) therapy is a challenge in patients with allergic rhinitis. We present a case of a 62-year-old male with OSA who had been struggling with PAP therapy for ten years. Intranasal fluticasone alone did not result in tolerance of PAP therapy.
View Article and Find Full Text PDFLaryngoscope
October 2024
Department of Otolaryngology-Head and Neck Surgery, Henry Ford Health, Detroit, Michigan, U.S.A.
Objective: Topical nasal decongestants (TNDs) are used to reduce nasal soft tissue edema and obstruction. However, after frequent TND use, patients can develop rhinitis medicamentosa (RM) with rebound nasal edema and obstruction. Management of RM has centered largely on TND cessation ± intranasal corticosteroids.
View Article and Find Full Text PDFExpert Opin Pharmacother
October 2024
Department of Otorhinolaryngology & Clinical Allergy Center, The First Affiliated Hospital, Nanjing Medical University, Nanjing, China.
Ugeskr Laeger
September 2024
Afdeling for Øre-Næse-Halskirurgi og Audiologi, Københavns Universitetshospital - Rigshospitalet.
J Multidiscip Healthc
March 2024
College of Medicine, Prince Sattam Bin Abdulaziz, Alkharj, Saudi Arabia.
Background: Rhinitis medicamentosa is a nonallergic inflammation of the nasal mucosa caused by topical decongestants overuse. It mainly affects young and middle-aged adults. Therefore, the aim of this study was to investigate the attitudes of pharmacists regarding the utilization of over-the-counter intranasal decongestants.
View Article and Find Full Text PDFJ Laryngol Otol
February 2024
Department of Otolaryngology - Head and Neck Surgery, Lady Davis Carmel Medical Center and Ruth and Bruce Rappaport Faculty of Medicine, and Technion - Israel Institute of Technology, Haifa, Israel.
Objective: Rhinitis medicamentosa poses a therapeutic challenge for both patients and physicians. Treatment strategies vary, starting with avoidance of decongestants, followed by medications or surgical intervention. This study aimed to compare two treatment strategies for this condition.
View Article and Find Full Text PDFEur Ann Otorhinolaryngol Head Neck Dis
November 2023
Université Clermont Auvergne, CHU Clermont-Ferrand, INRAE, UNH, équipe ASMS, 63000 Clermont-Ferrand, France; CHU de Clermont-Ferrand, service d'oto-rhino-laryngologie et chirurgie cervico-faciale, 63003 Clermont-Ferrand, France.
Introduction: We illustrate the diagnostic method for chronic nasal dysfunction by an observation in which the clinical history was compared to preoperative responses on the DyNaChron self-administered questionnaire, with ENT interpretation of the sinonasal CT scan preceding and guiding nasal endoscopy.
Case Report: The initial suspicion of rhinitis medicamentosa was transformed by the radiological and endoscopic findings of chronic respiratory rhinitis signs. Prick tests showing sensitivity to dust mites then suggested an allergic origin of the mucosal inflammation, which affected neither the olfactory nose nor the paranasal sinuses.
Int Forum Allergy Rhinol
December 2023
Department of Otorhinolaryngology-Head and Neck Surgery, Shengjing Hospital of China Medical University, Liaoning, China.
Int Forum Allergy Rhinol
March 2024
Rhinology and Skull Base Research Group, St Vincent's Centre for Applied Medical Research, University of New South Wales, Sydney, Australia.
Background: Limited treatment options exist for refractory Rhinitis Medicamentosa (RM). The role of surgery after failed medical management is not well defined. Mucosal contact points and restricted airflow often perpetuate decongestant use.
View Article and Find Full Text PDFAm J Otolaryngol
June 2023
Department of Otolaryngology-Head and Neck Surgery, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel(1). Electronic address:
Objective: Radiofrequency ablation (RFA) reliefs nasal obstruction and improves quality of life (QoL) in patients suffering from inferior turbinate hypertrophy (ITH). A substantial benefit was noted among patients suffering from Rhinitis Medicamentosa (RM), enabling ending decongestant spray abuse. Our aim was to establish the benefit from RFA with respect to QoL in patients suffering from ITH, due to the presence of RM.
View Article and Find Full Text PDFJ Allergy Clin Immunol Pract
February 2023
Pharmaceutical Care Unit, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.
Background: Rhinitis medicamentosa (RM) is a type of nonallergic rhinitis caused by prolonged use of nasal decongestants (NDs). Although it is a preventable phenotype of rhinitis, little is known about patients dealing with this condition.
Objective: To gain a better understanding of patients' views and experiences of ND overuse, and potential facilitators and barriers to discontinue the overuse.
Sisli Etfal Hastan Tip Bul
September 2022
Department of Biostatistics, Eastern Mediterranean University Faculty of Medicine, Famagusta, Cyprus.
Objectives: Nasal obstruction (NO) is a very common complaint in the practice of otolaryngology. The cause of NO can be due to inferior turbinate hypertrophy (ITH), which may be a result of allergic rhinitis, hyperreactivity, hormonal causes, rhinitis medicamentosa or idiopathic. The most commonly used treatments today include local nasal or systemic corticosteroids, cauterization or microdebrider, or thermal ablation with radiofrequency, coblation or ablative laser (mainly carbon dioxide or diode lasers), and submucosal reduction.
View Article and Find Full Text PDFJ Asthma Allergy
June 2022
Department of Clinical Research and Regulatory Affairs, Cadila Healthcare Limited, Ahmedabad, India.
Objective: To compare the efficacy and safety of a fixed dose combination of Fluticasone Furoate and Oxymetazoline Hydrochloride Nasal Spray 27.5/50 mcg (FDC) with Fluticasone Furoate Nasal Spray 27.5 mcg (Fluticasone) in the management of allergic rhinitis.
View Article and Find Full Text PDFAllergy
July 2022
Department of Otorhinolaryngology, Amsterdam UMC, Location Academic Medical Centre, Amsterdam, The Netherlands.
Background: Non-allergic rhinitis (NAR) can be subdivided into several phenotypes: rhinorrhea of the elderly, rhinitis medicamentosa, smokers', occupational, hormonal, drug-induced, gustatory, and idiopathic rhinitis. There are two pathophysiological endotypes of NAR: inflammatory and neurogenic. Phenotypes may serve as an indicator of an underlying endotype and, therefore, help to guide the treatment.
View Article and Find Full Text PDFHistol Histopathol
March 2022
Assistant Professor of Otorhinolaryngology, Private Corlu REYAP Hospital, Rumeli University, Istanbul, Turkey.
Objective: Our aim in this study is to reveal the expression of Vascular Endothelial Growth Factor (VEGF) and Inducible Nitric Oxide Synthase (iNOS) in the pathogenesis of rhinitis medicamentosa (RM), which occurs as a result of the overdose and long-term use of topical nasal decongestants.
Methods: In this study, 24 Wistar albino rats were divided into two groups as experimental and control groups. In the experimental group, 50 µl of 0.
BMJ Case Rep
November 2021
Department of Otolaryngology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
J Laryngol Otol
January 2022
Department of Otolaryngology - Head and Neck Surgery, Tripler Army Medical Center, Honolulu, USA.
ORL J Otorhinolaryngol Relat Spec
August 2021
Otorhinolaryngology Division, Department of Surgery, University of Eastern Piedmont "A. Avogadro", Novara, Italy.
Introduction: Radiofrequency turbinate volume reduction (RFTVR) is an effective treatment of inferior turbinate hypertrophy. RFTVR can reduce epithelial cell alterations in nasal mucosa. The aim of this observational study was to evaluate the effects of RFTVR on nasal obstruction and cytology, stratifying for different types of rhinitis.
View Article and Find Full Text PDFCMAJ
November 2020
Division of Allergy and Immunology (Pham), Department of Medicine, McGill University Health Centre, Montréal, Que.; Division of Neurology (Gosselin-Lefebvre), Centre hospitalier universitaire de Québec-Hôpital de l'Enfant-Jésus, Université Laval, Québec, Que.; Division of Allergy and Immunology (Pourshahnazari), University of British Columbia; Division of Neurology (Yip), Vancouver General Hospital, University of British Columbia, Vancouver, BC.
Curr Mol Pharmacol
October 2021
Department of Medical Biology, Gaziantep University Faculty of Medicine, Gaziantep, Turkey.
Vestn Otorinolaringol
August 2020
Volgograd State Medical University of the Ministry of Health of Russia, Volgograd, Russia.
One type of non-allergic non-infectious rhinitis is represented by a heterogeneous group of rhinitis medicamentosa, which can be divided into several pathogenetic types. The most common rebound nasal congestion associated with the use of topical decongestants. Excessive use of intranasal decongestants leads to a decrease in the number of alpha-adrenoreceptors on the surface of cell membranes and uncoupling their connection with the G-protein and the development of tachyphylaxis.
View Article and Find Full Text PDFRhinology
June 2020
"A. Gemelli" Hospital Foundation, IRCCS, Head and Neck Surgery Area, Institute of Otorhinolaryngology, Catholic University of the Sacred Heart. Rome, Italy.
Background: the primary end point of our study was to define risk factors and identify the underlying conditions that may have led to the abuse of vasoconstrictors in rhinitis medicamentosa. Moreover, we analysed factors that may influence the vasoconstrictors discontinuation.
Methodology: this was a prospective case-control observational study.
J Otolaryngol Head Neck Surg
December 2019
Department of Surgery, Division of Otolaryngology - Head and Neck Surgery, Dalhousie University, Halifax, Nova Scotia, Canada.
Background: Rhinitis medicamentosa is a non-allergic form of rhinitis that is typically caused by prolonged use of topical nasal decongestants. This condition commonly affects young adults and treatment is not trivial. We aimed to survey Canadian Otolaryngologists to determine practice patterns and their opinions regarding this under-studied condition.
View Article and Find Full Text PDFCochrane Database Syst Rev
November 2019
Academic Medical Centre, Department of Otorhinolaryngology, Meibergdreef 9, A2-234, 1105 Az, Amsterdam, Netherlands.